Fragile histidine triad (FHIT) and p53 gene inactivaton as response markers in non-small-cell lung cancer (NSCLC) patients treated with platinum-analogue regimen: Retrospective analysis

被引：0
|
作者：
Cortinovis, Diego
Bajetta, Emilio
Sozzi, Gabriella
Mariani, Luigi
Fabbri, Alessandra
Livio, Anna
Roz, Luca
Formisano, Barbara
Zilembo, Nicoletta
Bidoli, Paolo
机构：
[1] Ist Nazl Studio & Cura Tumori, Med Oncol Unit 2, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Stat Med Dept, I-20133 Milan, Italy
[4] Ist Nazl Studio & Cura Tumori, Anat Pathol Unit, I-20133 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [1] Predictive and prognostic role of fragile histidine triad (FHIT) and P53 gene inactivaton in non-small-cell lung cancer (NSCLC) patients treated with platinum-analogue regimen
    Cortinovis, D.
    Bajetta, E.
    Sozzi, G.
    Mariani, L.
    Fabbri, A.
    Livio, A.
    Roz, L.
    Andriani, F.
    Perego, P.
    Zilembo, N.
    Formisano, B.
    Bidoli, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI19 - XI19
  • [2] EXPRESSION OF FRAGILE HISTIDINE TRIAD AND P53 IN NON-SMALL CELL LUNG CANCER
    侯兴华
    张道荣
    Chinese Journal of Cancer Research, 2006, (02) : 121 - 126
  • [3] Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers
    Y-L Chang
    C-T Wu
    J-Y Shih
    Y-C Lee
    British Journal of Cancer, 2003, 89 : 320 - 326
  • [4] Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers
    Chang, YL
    Wu, CT
    Shih, JY
    Lee, YC
    BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 320 - 326
  • [5] P53 IN NON-SMALL-CELL LUNG-CANCER - RESPONSE
    MITSUDOMI, T
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (10) : 802 - 803
  • [6] Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib
    Bandera, M.
    Bascialla, L.
    Martinelli, B.
    Masera, G. L. Rodolfo
    Vallini, I.
    Zanlorenzi, L.
    Pinotti, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
  • [7] FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer
    Cortinovis, D. L.
    Andriani, F.
    Livio, A.
    Fabbri, A.
    Perrone, F.
    Marcomini, B.
    Pilotti, S.
    Mariani, L.
    Bidoli, P.
    Bajetta, E.
    Roz, L.
    Sozzi, G.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 342 - 348
  • [8] Characteristics of P53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
    Skrzypski, M
    Szymanowska, A
    Jassem, E
    Niklinski, J
    Jakobkiewicz-Banecka, J
    Dziadziuszko, R
    Kobierska-Gulida, G
    Rzyman, W
    Limon, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S145 - S145
  • [9] P53 AND DISEASE PROGRESSION IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    SAUTER, ER
    GWIN, JL
    MANDEL, J
    KELLER, SM
    SURGICAL ONCOLOGY-OXFORD, 1995, 4 (03): : 157 - 161
  • [10] The predictive value of clinical variables in patients affected with non-small-cell lung cancer (NSCLC) treated with pemetrexed (PEM) plus platinum-based regimen: A retrospective analysis.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Nelli, Fabrizio
    Gamucci, Teresa
    Mansueto, Giovanni
    Narducci, Filomena
    Quadrini, Silvia
    Sperduti, Isabella
    Passaro, Antonio
    Campenni, Giuseppe
    Cortesi, Enrico
    Martelli, Olga
    Bianchetti, Sara
    Angelini, Francesco
    Pellegrino, Arianna
    Pavese, Ida
    Signorelli, Carlo
    Ruggeri, Enzo Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345